

Springer Theses

Recognizing Outstanding Ph.D. Research

Aims and Scope

The series “Springer Theses” brings together a selection of the very best Ph.D. theses from around the world and across the physical sciences. Nominated and endorsed by two recognized specialists, each published volume has been selected for its scientific excellence and the high impact of its contents for the pertinent field of research. For greater accessibility to non-specialists, the published versions include an extended introduction, as well as a foreword by the student’s supervisor explaining the special relevance of the work for the field. As a whole, the series will provide a valuable resource both for newcomers to the research fields described, and for other scientists seeking detailed background information on special questions. Finally, it provides an accredited documentation of the valuable contributions made by today’s younger generation of scientists.

Theses are accepted into the series by invited nomination only and must fulfill all of the following criteria

- They must be written in good English.
- The topic should fall within the confines of Chemistry, Physics, Earth Sciences, Engineering and related interdisciplinary fields such as Materials, Nanoscience, Chemical Engineering, Complex Systems and Biophysics.
- The work reported in the thesis must represent a significant scientific advance.
- If the thesis includes previously published material, permission to reproduce this must be gained from the respective copyright holder.
- They must have been examined and passed during the 12 months prior to nomination.
- Each thesis should include a foreword by the supervisor outlining the significance of its content.
- The theses should have a clearly defined structure including an introduction accessible to scientists not expert in that particular field.

More information about this series at <http://www.springer.com/series/8790>

Rajni M. Bhardwaj

Control and Prediction of Solid-State of Pharmaceuticals

Experimental and Computational Approaches

Doctoral Thesis accepted by
the University of Strathclyde, Scotland, UK

 Springer

Author

Dr. Rajni M. Bhardwaj
Lilly Corporate Center
Eli Lilly and Company
Indianapolis, IN
USA

Supervisor

Prof. Alastair J. Florence
EPSRC Center for Innovative
Manufacturing in Continuous
Manufacturing and Crystallisation,
CMAC, Technology and Innovation
Center
University of Strathclyde
Glasgow
Scotland, UK

ISSN 2190-5053

Springer Theses

ISBN 978-3-319-27554-3

DOI 10.1007/978-3-319-27555-0

ISSN 2190-5061 (electronic)

ISBN 978-3-319-27555-0 (eBook)

Library of Congress Control Number: 2015958540

© Springer International Publishing Switzerland 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by SpringerNature

The registered company is Springer International Publishing AG Switzerland

Parts of this thesis have been published in the following journal articles:

1. **Rajni M. Bhardwaj**, Andrea Johnston, Blair Johnston and Alastair J. Florence. *A Random Forest Model for Predicting the Crystallisability of Organic Molecules*. CrystEngComm 2015, 17, 4272–4275.
2. **Rajni M. Bhardwaj**, Jean-baptiste Arlin and Alastair J. Florence. *Crystal structure of a mixed solvated form of amoxapine acetate*. Acta Cryst., 2015, E71, 139–141
3. **Rajni M. Bhardwaj**, Louise Price, Sarah L. Price, Susan M. Reutzel-Edens, Iain Oswald, Blair Johnston and Alastair J. Florence. *Exploring the Experimental and Computed Crystal Energy Landscape of Olanzapine*. Cryst. Growth Des., 2013, 13, 1602–1617.
4. **Rajni M. Bhardwaj**, Iain Oswald, Blair Johnston and Alastair J. Florence. *A Complementary Experimental and Computational Study of Loxapine Succinate and its Monohydrate*, Acta Crystallogr C., 2013, 69, 1273–1278.
5. **Rajni M. Bhardwaj** and Alastair J. Florence. *2-Methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine (olanzapine) propan-2-ol Disolvate*. Acta Cryst., 2013, E69, o752–o753.

Other Publications

6. **Rajni M. Bhardwaj**, Huaiyu Yang and Alastair J. Florence. *Crystal structure of the co-crystal butyl paraben-isonicotinamide (1/1)*. Acta Cryst., 2016, E72, 53–55.
7. Lihua Zhao, Vishal Raval, Naomi E. B. Briggs, **Rajni M. Bhardwaj**, Thomas McGlone, Iain D. H. Oswald and Alastair J. Florence. *From Discovery to Scale-up: α -Lipoic Acid: Nicotinamide Co-crystals in a Continuous Oscillatory Baffled Crystalliser*. CrystEngComm, 2014, 16, 5769–5780. (Cover Page article)
8. Amit Delori, Pauline Maclure, **Rajni M. Bhardwaj**, Andrea Johnston, Alastair J. Florence, Oliver B. Sutcliffe and Iain D.H. Oswald. *Drug Solid Solutions—A Method for Tuning Phase Transformations*. CrystEngComm, 2014, 16, 5827–5831.
9. Elanor Brammer, Fraser Mabbott, Laura Martinez-Marcos, **Rajni M. Bhardwaj** “*Continuous Manufacturing—A paradigm shift in the Pharmaceutical Industry*”. UKICRS Newsletter 2014, 29–32.
10. Doris E. Braun, **Rajni M. Bhardwaj**, Jean-Baptiste Arlin, Alastair J. Florence, Volker Kahlenberg, Ulrich J. Griesser, Derek A. Tocher and Sarah L. Price. *Absorbing a Little Water: The Structural, Thermodynamic and Kinetic Relationship Between Pyrogallol and its Tetarto-hydrate*. Cryst. Growth Des., 2013, 13, 4071–4083.

11. Doris Braun, **Rajni M. Bhardwaj**, Alastair J. Florence, Derek A. Tocher and Sarah L. Price. *The Complex Polymorphic System of Gallic Acid—Five Monohydrates, Three Anhydrates and Over 20Solvates*. Cryst. Growth Des., 2013, 13, 19–23.
12. **Rajni M. Bhardwaj**, Iain Oswald and Alastair J. Florence. *2,4-Diamino-6-methyl-1,3,5-triazine 1,4-butanediol Solvate*. Acta Cryst., 2012, E68, o3377.
13. Jean-Baptiste Arlin, **Rajni M. Bhardwaj**, Andrea Johnston, Gary J. Miller, Julie Bardin, Fiona MacDougall, Philippe Fernandes, Kenneth Shankland, Bill David and Alastair J. Florence. *Structure and Stability of Two Polymorphs of Creatine and its Monohydrate*. CrystEngComm, 2014, 16, 8197–8204.

Supervisor's Foreword

Crystallisation is an important process for purification and isolation of active pharmaceuticals and other chemicals, yet the critical factors that dictate the outcome for a given molecule under any given set of process conditions often remain unclear. Hence the identification and selection of potential crystalline forms during the development of new products still largely relies on empirical relationships and user experience to select initial experimental conditions and maximise the number of solid forms discovered. Whilst crystal structure prediction can be applied to increasingly complex molecular systems (flexible molecules; multi-component systems), it is still far from routine, and has the potential to inform experimental approaches by revealing the structural features and trends in feasible crystal packing arrangements. The work presented in this thesis seeks to develop improved experimental approaches for exploring physical form diversity in molecular systems and to exploit computational methods to provide a better understanding of the outcomes of such investigations as well as novel, computationally inexpensive, predictive capabilities. The work focuses on a structurally related series of molecules and provides insights into the differences that can result in crystallisation from small changes in molecular structure in such related systems.

Cost-effective, safe, rapid and sustainable methods for exploring solid-state diversity are of significant interest in academic research as well as industry. The development of a small-scale screening approach using manual multiwall plate preparation and Raman microscopy for effective salt, polymorph and solvate screening provides an effective means to generate structural diversity from only small amounts of material. The quality of this work has been recognised by the RSC "Duncan Bryant Prize" prize in 2012. The next experimental chapter shows the potential to build predictive capability based on the outcomes of such systematic experimental studies. At present we have no means of assessing 'crystallizability' of molecules-based molecular structure alone and so can be surprised by individual molecules' behaviour. The crystallizability prediction tool developed in this work emphasises the potential for multivariate statistical approaches combined with systematic experimentation to provide some useful predictive capability. In the

context of solid form discovery and preclinical development, if such approaches can be extended to cover a diverse range of molecules then there are considerable benefits in the early identification of problem compounds. The work on olanzapine solvates also highlights the potential to further extend the application of these tools to understand the crystal structure and molecular packing obtained from experimental tools and build a useful knowledge base that can inform future experiments for successful outcomes. The success of the work in this thesis has ensured that these approaches continue to be developed for application in other molecular systems. The detailed study on polymorphism and crystal packing in olanzapine is a showcase for the potential for combined crystal structure prediction, molecular modelling, packing analysis and intermolecular interactions to reveal the key features directing crystal structure. Crucially, this work also reveals key structure–property relationships enabling the rationalisation of the observed stability of solvated forms.

Overall, the work illustrates the potential for computationally assisted experimentation not just to provide more data, but also better information describing the factors that influence crystallisation and crystal structure. Moreover, it highlights the possibilities to improve the efficiency of early stage solid form discovery and selection. Whilst challenges remain for first principles prediction from molecular structure alone, there is still much more that can be achieved with existing tools. The work presented here continues to influence research in our group that seeks to extend the development and application of statistical models to assess completeness of physical form screens and enhance our understanding of crystal structure outcomes. It has also influenced our approach to training and skills development for researchers in this area to enable the increased use of multivariate analysis tools, molecular modelling and structure prediction alongside careful experimentation and analysis.

Glasgow, Scotland, UK
December 2015

Prof. Alastair J. Florence Ph.D

Abstract

This thesis illustrates techniques for discovery of solid-state forms and for probing the relationship between molecular structure and crystallisability. Also, the value of combined experimental and computational approaches to provide better understanding of the key factors underpinning the structural diversity in two groups each comprising of two structurally related pharmaceutical compounds is demonstrated.

An effective methodology of high throughput crystallisation and analysis for polymorph, solvate and salt screening using quartz 96/48 multi-well plate with an automated system for collecting high quality Raman spectra was developed and validated. Using this efficient technique, 10 novel salts of amoxapine, 3 novel physical forms of clozapine and 16 novel solid forms of olanzapine were obtained by utilising a total of only ~640 mgs of API and ~65 ml of solvents.

A statistical model with ~70 % prediction accuracy was built for predicting the crystallisability of small organic molecules. This model is the first of its kind and provides an opportunity to identify problematic systems at early stages and allows early targeting for improvements.

Structurally related molecules within each group were found to have markedly different experimental solid-state diversity after comprehensive physical form screening using multiple crystallisation techniques selected to maximise the crystallisation search space. Crystal structure prediction studies have proved to be an important tool in rationalisation of the observed solid-state diversity. PIXEL calculations revealed that the largest contribution to crystal stabilisation comes from dispersion energy and enabled the identification of dominant intermolecular interactions in the crystal structures. Structural packing analysis using XPac and mercury enabled the structural relationship amongst all the crystal structures to be investigated. In the case of olanzapine solvates XPac analysis provides a rationale for desolvation products by highlighting the close relationships between the forms and desolvated 'end product'. Statistical modelling analysis revealed that the physicochemical properties of the solvents were directing the crystal packing in olanzapine solvates.

Acknowledgments

First and foremost, I would like to thank my supervisor, Prof. Alastair J. Florence for his invaluable guidance, encouragement, support and advice throughout the course of my Ph.D. I would like to express my gratitude to the Commonwealth Scholarship Commission in the United Kingdom (UK) and the British Council for sponsoring my studies and all the support during my stay.

I also thank my co-supervisors Dr. Iain Oswald and Dr. Blair Johnston for their guidance and support throughout my research. The contribution of Prof. Sarah Price and Louise Price for crystal structure prediction studies is also acknowledged. Numerous advices from Susan Reutzel-Edens during studies on olanzapine are appreciated. Many thanks to Dr. Andrea Johnston for her support and advice during statistical modelling and experimental work.

Many thanks to Dr. Gary Miller for his help with XPac analysis. Thanks to Mr. Vishal Raval for his timely help with the experimental work. Thanks are also due to Dr. Julie Bardin for CASTEP calculations, Dr. Catriona Morrison regarding the use of PIXEL, Dr. Dimitrois Lamprou for his help during preparation of various surfaces, Master students Eugene and Paula for their help with the experimental work. The use of National Grid service facilities, UK, for CASTEP calculations is also acknowledged.

Thanks are due to everyone from the solid-state research group, and CMAC particularly Dr. Jean-Baptiste Arlin, Dr. Scott Mckellar, Dr. Ryan Taylor, Naomi Briggs, Dr. Thomas Mcglone, Dr. Lihua Zhao, Dr. Anna Jawor-Baczynska and Lorna.

Finally, I would like to thank my family and friends for their support throughout my Ph.D.

Contents

1	Introduction	1
1.1	Background	1
1.2	Polymorphism	3
1.3	Multi-component Crystalline Systems: Solvates, Salts and Co-crystals	4
1.4	Amorphous Solids	6
1.5	Importance of Solid-State Form for Pharmaceutical Industry	6
1.6	Crystallisation	7
1.7	Crystallisation Techniques	8
1.8	Control of Solid Form	10
1.9	Computational Methods	13
1.9.1	Crystal Structure Prediction	13
1.9.2	Energetics of Non-bonded Interactions: The PIXEL/Semi-classical Density Sums Methods	16
1.10	Experimental and Computational Studies on Structurally Related Compounds	18
	References	23
2	Aims and Objectives	29
2.1	Aims	29
2.2	Objectives	30
3	Materials and Methods	31
3.1	Material	31
3.2	Methods	31
3.2.1	Crystallisation Techniques	31
3.2.2	X-Ray Crystallography	33
3.2.3	Thermal Analysis	35
3.2.4	Raman and Infrared Spectroscopy	35
3.2.5	PIXEL Calculations	35
3.2.6	Crystal Packing Analysis	36
	References	36

4	Development and Validation of High-Throughput Crystallisation and Analysis (HTCAA) Methodology for Physical Form Screening	39
4.1	Introduction	39
4.2	Sample Preparation and Methodology Development	45
4.2.1	96/48 Quartz Multi-well Plate	45
4.2.2	Preparation of 96-Well Plate for Salt Screening of Amoxapine	46
4.2.3	Preparation of 48-Well Plate for Physical Form Screening of Clozapine	47
4.2.4	Preparation of 96-Well Plate for Physical Form Screening of Olanzapine	47
4.2.5	Raman Microscopy	49
4.2.6	Chemometric Analysis	50
4.2.7	Scale-up and Characterisation of Novel Forms	51
4.3	Results and Discussion	52
4.3.1	Salt Screening of Amoxapine	52
4.3.2	Physical Form Screening of Clozapine	60
4.3.3	Physical Form Screening of Olanzapine	65
4.4	Key Findings of the Developed HTCAA Methodology	70
4.5	Summary	73
	References	74
5	Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques	77
5.1	Statistical Modelling Techniques	77
5.1.1	Introduction	77
5.1.2	Principal Component Analysis	78
5.1.3	Criteria for Deciding the Number of Principal Components	79
5.1.4	Random Forests Classification Method	80
5.1.5	Applications of Statistical Modelling Techniques in Pharmaceutical Industry	82
5.2	Descriptor Calculations, Model Building and Validation	86
5.2.1	Training Dataset and 2- and 3-Dimensional Descriptors Calculations	86
5.2.2	Training the Statistical Model	88
5.3	Results and Discussion	88
5.3.1	Principal Component Analysis	88
5.3.2	Random Forests Classification Model	89
5.3.3	Model Optimisation Attempts	91
5.3.4	Important Descriptors Assessment	93
5.3.5	Limitations of Random Forests Classification Model	94
5.4	Summary	95
	References	95

6	Exploring the Crystal Structure Landscape of Olanzapine	99
6.1	Introduction.	99
6.2	Experimental Procedures.	102
6.2.1	Crystallisation	102
6.2.2	Variable Temperature-X-Ray Powder Diffraction	105
6.2.3	XPac Analysis of Crystal Structures of Olanzapine.	105
6.2.4	Random Forests Classification Model of Olanzapine Solvates	106
6.3	Calculation and Analysis of the Crystal Energy Landscape (Crystal Structure Prediction) of Olanzapine	106
6.4	Results and Discussion	109
6.4.1	Forms I, II and III of Olanzapine	109
6.4.2	Solution Crystallisation of Olanzapine	112
6.4.3	Neat and Liquid-Assisted Grinding of Olanzapine	118
6.4.4	Desolvation of Olanzapine Solvates	120
6.4.5	Melt Quenching and Recrystallisation of Amorphous Olanzapine	120
6.4.6	Spray Drying and Freeze Drying of Olanzapine	123
6.5	Molecular Packing Analysis of Olanzapine Crystal Structures Using XPac.	123
6.6	Hydrogen-Bonding Analysis of Olanzapine Crystal Structures	127
6.6.1	Hydrogen Bonding in Olanzapine Solvates Based on Packing Type SC ₃₁	129
6.6.2	Hydrogen Bonding in Olanzapine Solvates Based on Packing Type SC ₃₂	129
6.6.3	Hydrogen Bonding in Olanzapine Solvates Based on Packing Type, SC ₃₃	130
6.6.4	Hydrogen Bonding in Other Olanzapine Solvates Based on SC ₀ , SC ₁₁ and SC ₂₂	131
6.7	Prediction of Olanzapine Solvate Formation Using Random Forests Classification Model	132
6.7.1	Random Forests Classification Model – Prediction Results	132
6.7.2	Important Solvent Physicochemical Descriptors for Random Forests Classification Model of Olanzapine Solvates	136
6.8	Crystal Energy Landscape of Olanzapine	138
6.9	PIXEL Calculations on Olanzapine	141
6.10	Concomitant Appearance of Form III with Other Polymorphs of Olanzapine	144
6.11	Prolific Solvate Formation of Olanzapine	145

6.12	Challenges with Crystal Structure Prediction of Olanzapine and Unobserved Calculated Structures	146
6.13	Summary	147
	References	148
7	Exploring the Physical Form Landscape of Clozapine, Amoxapine and Loxapine.	153
7.1	Introduction.	153
7.1.1	Background of Molecule in Group 1-Clozapine	154
7.1.2	Background of Molecules in Group 2-Amoxapine and Loxapine.	154
7.2	Experimental Details	155
7.2.1	Principal Component Analysis of Solvent Properties.	155
7.2.2	Crystallisation Experiments of Clozapine	155
7.2.3	Crystallisation Experiments of Amoxapine	155
7.2.4	Crystallisation Experiments of Loxapine	156
7.2.5	Preliminary Crystal Structure Prediction Studies for Clozapine, Amoxapine and Loxapine.	158
7.2.6	Solid-State Calculations Using CASTEP.	158
7.2.7	Structure Analysis	159
7.3	Results and Discussion	159
7.3.1	Physical Form Screening of Clozapine	159
7.3.2	Physical Form Screening Results of Amoxapine.	173
7.3.3	Physical Form Screening Results of Loxapine	178
7.4	Summary	190
	References	191
8	Conclusions and Further Work	195
8.1	Conclusions and Further Work	195
8.1.1	Development and Validation of High Throughput Crystallisation and Analysis Methodology for Physical Form Screening	198
8.1.2	Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques.	198
8.1.3	Exploring the Physical Form Landscape of Structurally Related Pharmaceutical Molecules in Group 1 (Olanzapine and Clozapine) and 2 (Amoxapine and Loxapine)	199
8.2	Further Work	201
8.2.1	Development and Validation of High Throughput Crystallisation and Analysis Methodology for Physical Form Screening	201
8.2.2	Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques.	202

8.2.3	Exploring the Physical Form Landscape of Structurally Related Pharmaceutical Molecules in Group 1 (Olanzapine and Clozapine) and 2 (Amoxapine and Loxapine)	203
	References	204
Appendix	207

List of Figures

Figure 1.1	Schematic illustration of molecular arrangements of different solid forms showing ordered arrangement in crystalline forms and molecule disorder in amorphous form. Reproduced from reference (Florence 2009)	2
Figure 1.2	a Molecular structure of carbamazepine, b dimer motif of carbamazepine present in form I–IV (Florence et al. 2006), and c catameric motif of carbamazepine present in form V (Arlin et al. 2011)	3
Figure 1.3	a Extended conformation of L-glutamic acid which leads to the β -polymorph (CSD refcode: LGLUAC11), and b twisted conformation of L-glutamic acid which leads to α -polymorph (CSD refcode: LGLUAC03).	4
Figure 1.4	Multi-component systems and their overlap with each other. Reproduced from reference (Aitipamula et al. 2012)	5
Figure 1.5	Plausible scenarios of crystallisation outcome in a dimorphic system under different circumstances. Polymorph A has higher free energy barrier (ΔG) to nucleation than polymorph B and is the stable form. Adapted from reference (Aaltonen et al. 2009)	8
Figure 1.6	Timescale of various crystallisation techniques, which is also highlighting the techniques which can be used to obtain stable and metastable crystal forms. Adapted from reference (Anderton 2007; Llinàs and Goodman 2008)	9
Figure 1.7	Schematic illustration of factors controlling the polymorphic outcome in crystallisation processes. Reproduced from reference (Kitamura 2003)	11

Figure 1.8	Schematic examples of the crystal energy landscapes; a , b , c and d denote monomorphic, predictive, complex and interchangeable crystal energy landscapes respectively. Each point denotes a crystal structure that is a local energy minimum, with the symbols representing significantly different type of packing such as different hydrogen bonding motifs. The experimentally known structures are denoted by empty <i>red</i> symbols. Reproduced from reference (Price 2009).	14
Figure 1.9	Chemical Structures of (a) hydrochlorothiazide and (b) chlorothiazide	19
Figure 1.10	Polymorphs and hydrogen bonding motifs observed in carbamazepine and its analogues. The number of polymorphs having particular motif are shown in parentheses. *For oxycarbamazepine, only crystal structures of two polymorphs are known	20
Figure 1.11	Chemical structures of (a) fenamic acid (monomorphic) and (b) tolfenamic acid (5 polymorphs)	21
Figure 1.12	Molecular structures of fenamic acid analogues. The number of structurally characterised polymorphs for each compound is written in parentheses. Reproduced from reference (López-Mejías et al. 2012).	22
Figure 2.1	The four compounds studied in this thesis. The differences in the chemical structures within a group are highlighted in <i>red</i>	30
Figure 4.1	Illustration of experimental workflow for high-throughput crystallisation and analysis methodology.	42
Figure 4.2	Calculated pKa of nitrogen atoms in amoxapine	44
Figure 4.3	Chemical structures of olanzapine and clozapine	45
Figure 4.4	Layout of a salt screening in the 96-well plate, and b anti-solvent screening in the 48-well plate. A polymorph screen could be carried out using a different solvent in each well for example	45
Figure 4.5	DXR Raman microscope with motorised x, y, z stage and multi-well plate reader	49
Figure 4.6	A screenshot of the data acquisition interface set-up for use with the bespoke 96-well quartz plate. Each <i>circle</i> in the 8 × 12 grid (<i>top left</i>) represents a well on the plate and each <i>square</i> within a well represents a point of data collection (i.e. a Raman spectrum). The point (spot size-1 μm) from where the spectrum is being collected is shown by a plus sign on the image (<i>top right</i>) with the respective	

	Raman spectrum shown (<i>bottom</i>). Spectra in the grid are coloured based on the magnitude of the measured Raman intensity. <i>Red</i> and <i>violet colours</i> indicate the highest and lowest intensity respectively	50
Figure 4.7	Salt screening results of amoxapine after group analysis on a 96-well plate. Each <i>square</i> (spectrum) from the wells is colour coded according to classification group. Group 1 to 11 are shown by <i>blue, fluorescent green, dark orange, cyan, green, yellow, orange, dark yellow, light green, pink-red</i> and <i>violet</i> colour respectively. All other spectra shown by <i>violet colour</i> are outliers	52
Figure 4.8	Characteristic Raman spectra for 10 novel salts observed during salt screening of amoxapine. Each spectrum is labelled according to the well number from which they have been obtained on the 96-well plate	54
Figure 4.9	Stack plots of Raman spectra collected from samples of salts of a amoxapine and succinic acid, b amoxapine and acetic acid, at 96-well plate and on 150 mg scales. The Raman spectra of salts obtained from 96-well plate and on 150 mg scales are labelled in <i>black</i> and <i>blue colour</i> respectively.	56
Figure 4.10	Stack plot of XRPD patterns of the 10 novel amoxapine salts obtained on 150 mg scales in the range of 4–35° 2 θ	57
Figure 4.11	Microscope images (20 \times) of the M2 crystals observed in wells C8, D4 and D12 of 96-well plate	58
Figure 4.12	Stack plots of Raman spectra collected from samples of salts of a amoxapine and maleic acid and b amoxapine and para-toluene sulfonic acid at 96-well plate and on 150 mg scales. The Raman spectra of salts obtained from 96-well plate and on 150 mg scales are labelled in <i>black</i> and <i>blue</i> respectively.	59
Figure 4.13	Physical form screening (PS-1) results of clozapine after group analysis on the 48-well plate using the conditions shown in Table 4.12. The wells are <i>colour</i> coded according to classification group. Group 1, 2, 3, 4 and 5 are shown by <i>green, blue, orange, red</i> and <i>yellow colour</i> , respectively. All other spectra shown by <i>magenta colour</i> are outliers	61
Figure 4.14	Overlay of Raman spectra in the region of 1450–1700 cm ⁻¹ of Raman shift for four physical forms (A, B, C and D) observed during physical form screening of clozapine	61

Figure 4.15	Physical form screening (PS-2) results of clozapine after group analysis on the 48-well plate using the conditions shown in Table 4.13. The wells are colour coded according to classification group. Group 1, 2, 3 and 4 are shown by <i>blue, green, orange</i> and <i>yellow colour</i> , respectively. All other spectra shown by <i>magenta colour</i> are outliers	63
Figure 4.16	Stack plot of the Raman spectra collected from samples of physical forms of clozapine observed on the 48-well plate and on 150 mg scales. The Raman spectra are labelled according to the source of their origin	64
Figure 4.17	Stack plot of the characteristic XRPD patterns of the 3 physical forms of clozapine obtained on 150 mg scales in the range of $4\text{--}35^\circ 2\theta$. CZPN_anhydrous, CZPN_amorphous and CZPN_monohydrate represent form A, C, and B observed on the 48-well plate	64
Figure 4.18	Characteristic Raman spectra in the $1480\text{--}1650\text{ cm}^{-1}$ region for 7 novel physical forms and form I of olanzapine identified during HTCAA. Spectra are coloured and labelled according to the well from which they have been detected	66
Figure 4.19	Stack plot of Raman spectra collected from samples of physical forms of olanzapine at 96-well plate (<i>black colour</i>) and 150 mg scales (<i>blue colour</i>).	67
Figure 4.20	Raman spectra of isostructural methanol and ethanol solvates of olanzapine	68
Figure 4.21	Raman spectra of isostructural hydrated solvates of olanzapine.	69
Figure 4.22	Stack plot of XRPD patterns of the 16 novel solvates and form I of olanzapine obtained on 150 mg scales. Abbreviations used in the figure are: THF-tetrahydrofuran, CH ₃ CN-acetonitrile, MXE-2-methoxyethanol, DMSO-dimethylsulfoxide, TFE-2,2,2-trifluoroethanol and IAA-isoamyl alcohol	69
Figure 4.23	Raman spectra of the sample exhibiting fluorescence (<i>red</i>) and after applying fluorescence correction (<i>black</i>)	72
Figure 5.1	Schematic workflow of various stages of a typical statistical modelling process	78
Figure 5.2	Principal component analysis. Reproduced from reference (Wiklund 2008).	78
Figure 5.3	Example of score and loading plots obtained from principal component analysis while investigating the patterns of food consumption of 20 food products in 16 countries. Score and loading plots relate to observations	

	(countries in this case) and variables (food products in this case) respectively. Reproduced from reference (Wiklund 2008)	79
Figure 5.4	Scree plot of the number of principal components versus eigenvalues. Adapted from reference (Xu and Redman-Furey 2007)	80
Figure 5.5	Schematic workflow of building of random forests model.	81
Figure 5.6	Basic skeleton of acylanilide molecules, R and X represent the two points of modifications. X includes H, CH ₃ , C ₂ H ₅ , C ₃ H ₇ , C(CH ₃) ₃ , CF ₃ , OCH ₃ , OC ₂ H ₅ NH ₂ and Cl. R includes H, CH ₃ , C ₂ H ₅ , C(CH ₃) ₃ , OCH ₃ , OC ₂ H ₅ , OCF ₃ , F, Cl, Br, I, CF ₃ , OH, NH ₂ and COOH	87
Figure 5.7	<i>Scatter plot</i> of properties of molecules, shown with an <i>ellipse</i> that represents the Hotelling T2 with 95 % confidence. Each of the 382 points on the <i>plot</i> represents a molecule from the dataset. Molecules are coloured according to the crystallisation outcome: class 1 (<i>crystals, red</i>) and class 2 (<i>no crystals, black</i>).	89
Figure 5.8	Error plot for the random forests classification model trained using 2-D and 3-D molecular descriptors of the molecules present in the dataset. <i>Blue line</i> shows the evolvement of overall OOB error of prediction with the addition of number of trees.	89
Figure 5.9	The multidimensional scaling plot of the scaling coordinates (1, 2) obtained from the random forests classification proximity matrix. Each of the 382 points on the multidimensional scaling <i>plot</i> represents a molecule from the dataset and is coloured according to crystallisation outcome: class 1 (<i>red</i>) and class 2 (<i>blue</i>). 1 and 2 denote the two separate zones correspond to molecules from class 1 and class 2. 3 (<i>encircled in green</i>) denotes the overlapped zone with molecules from both classes	90
Figure 5.10	Convex hull plot of scaling coordinates obtained from random forests classification proximity matrix. Molecules in class 1 and 2 are represented by <i>red</i> and <i>green points</i> respectively. The <i>cross sign</i> is the mean of MDS1 and MDS2 for each group.	91
Figure 5.11	Two different conformation of propyl chains in 4-methylbutylanilide. Reproduced from reference (Hursthouse et al. 2009)	93

Figure 5.12	Alternate conformations of meta-substituted acylanilides. The rotation is around aromatic carbon to N bond. Reproduced from reference (Hursthouse et al. 2009)	94
Figure 6.1	Molecular structure of olanzapine	100
Figure 6.2	Centrosymmetric dimer observed in all the experimental crystal structures of olanzapine	102
Figure 6.3	Common ordered sets of points selected for XPac analysis	105
Figure 6.4	The difference between the observed conformation (region A, coloured by element) and the alternative low energy conformation (region B, coloured by <i>orange</i>) depicted by overlaying (<i>left</i>) the benzodiazepine or (<i>right</i>) the piperazine rings, of the gas phase optimised conformations	107
Figure 6.5	The CrystalPredictor grid of intramolecular energies ΔE_{intra} , in kJ mol^{-1} relative to the lowest energy point in each region shown in Fig. 6.4	107
Figure 6.6	The molecular structure of olanzapine, showing all degrees of flexibility considered in final CrystalOptimizer refinements ($\text{C}_{11}\text{-C}_{10}\text{-N}_3\text{-C}_{12}$, $\text{C}_{10}\text{-N}_3\text{-C}_{12}\text{-C}_{13}$, $\text{H-C}_{17}\text{-N}_4\text{-C}_{13}$, $\text{C}_{17}\text{-N}_4\text{-C}_{13}\text{-C}_{12}$ and $\text{H-C}_{16}\text{-C}_2\text{-C}_1$).	108
Figure 6.7	Overlay of XRPD patterns of form I (experimental, <i>black</i>), form II (simulated from room temperature single crystal structure, <i>blue</i>) and III + II (experimental, <i>green</i>) of olanzapine. Characteristic peaks of form III are marked	109
Figure 6.8	DSC thermograms from samples of olanzapine a form I, b form II, sample comprising of several single crystals, c form III + II	110
Figure 6.9	Raman spectra of form I (<i>blue</i>), form II (<i>red</i>) and form III + II (<i>green</i>).	111
Figure 6.10	FT-IR spectra of form I, II (major) + III (minor), III (major) + II (minor) and amorphous phase of olanzapine	111
Figure 6.11	XRPD patterns of the 18 novel isostructural solvates (belong to crystal structures in space group $\text{C}2/c$) observed during experimental screen and a reference pattern of the known olanzapine DMSO hydrate	118
Figure 6.12	XRPD patterns of the four novel olanzapine solvates obtained from crystallisation on the automated platform	119
Figure 6.13	Pawley fit in TOPAS Academic (version 4.1), observed profile (<i>blue</i>), calculated profile (<i>red</i>) and difference plot (<i>black</i>) of the Pawley fit for form II in the range of $6\text{-}39^\circ$ 2θ . $R_{\text{wp}} = 2.461$	119

Figure 6.14	3-D overlay of the XRPD patterns during in-situ desolvation of olanzapine DCM solvate at 318 K, showing appearance of peaks of form III and II and disappearance of peaks of DCM solvate	121
Figure 6.15	XRPD data of amorphous olanzapine in the region of 2–40° 2 θ	121
Figure 6.16	DSC data of amorphous olanzapine. Data was collected from 263 to 483 K at a heating rate of 20 K min ⁻¹	122
Figure 6.17	XRPD data in the range 6–30° 2 θ collected from melt-quenched sample of olanzapine recrystallised within boro-silicate capillary or in a vial held at RT or at 313 K.	122
Figure 6.18	Diagram showing the similarity relationship between 35 structures of olanzapine with structures identified by the crystal structure numbers used in Table 6.7.	125
Figure 6.19	Packing diagrams highlighting the supramolecular constructs (SCs) and their relationships highlighted in Fig. 6.18. The directions of the primary vectors are indicated by arrows and in the SC ₂₁ layer the SC ₀ pairs are differentiated by <i>light</i> or <i>dark blue shading</i> . As the three-dimensional arrays correspond to three distinct packing modes of the SC ₂₁ layers these are all viewed along the direction of the <i>t</i> ₂ vector with the constituent SC ₂₁ layers differentiated by <i>dark</i> and <i>light blue shading</i> . The three one-dimensional SCs are coloured <i>green</i> (SC ₁₁), <i>purple</i> (SC ₁₂) and <i>red</i> (SC ₁₃) respectively and are viewed perpendicular to the axis of their translation vectors. In SC ₃₁ and SC ₃₂ , the SC ₂₁ layers are related by the SC ₁₃ and SC ₁₁ constructs respectively and a single occurrence of each, viewed perpendicular to its translation vector, is highlighted with the corresponding colour. A single SC ₂₂ layer is shown with the SC ₁₂ component running approximately vertical, highlighted in purple, with three SC ₁₁ constructs running horizontally and differentiated by <i>dark</i> and <i>light green shading</i>	126
Figure 6.20	The five different packing arrangements adopted by the SC ₁₁ stacks, these are viewed along the axis of the <i>t</i> ₄ vector (which run perpendicular to page) with each pair of face-to-face molecules (<i>coloured yellow</i>) representing a single SC ₁₁ stack. In the dichloromethane solvate the <i>dark red</i> molecules represent SC ₁₁ columns in which the <i>t</i> ₄ vector runs perpendicular to those in the neighbouring layers, in form I and dihydrate D, a SC ₂₂ layer is shown by the <i>green</i> molecules	127

Figure 6.21	Different arrangements of SC ₁₁ in a form I and b II of olanzapine, which share the same H-bonding (shown by <i>green dotted line</i>). c A closer view at the olanzapine atoms involved in H-bonding. Other hydrogen atoms are omitted for clarity	128
Figure 6.22	Three water H-bonding environments observed in family of olanzapine solvate crystal structures, (D-Donor, A-acceptor). Weak interactions such as C-H...O were not included in the analysis. Reproduced from reference (Clarke et al. 2010)	129
Figure 6.23	a Hydrogen bonds (N1H...N4) between centrosymmetric dimers, conciliated by water molecules present within SC ₂₁ sheet of olanzapine 1,4-dioxane solvate hydrate. H-bonds are shown by <i>blue dotted lines</i> b organic solvent molecule surrounded by 4 pairs of centrosymmetric dimers from adjacent SC ₂₁ sheets (coloured by <i>blue</i> and <i>cyan</i>), arranged in a staggered manner. Other hydrogen atoms are omitted for clarity	130
Figure 6.24	a Olanzapine acetic acid solvate in which acetic acid links the centrosymmetric dimers through N1H...N4 H-bonds. b Olanzapine ethylene glycol solvate, where each olanzapine molecule is involved in three H-bonds (N1H, N2 and N4) with solvent molecules. H-bonds are shown by <i>blue dotted lines</i> . Other hydrogen atoms are omitted for clarity	130
Figure 6.25	a Catemer arrangement of water molecules in olanzapine t-butanol solvate hydrate. b Water molecules exist in type 2 environment in olanzapine TBMe solvate hydrate. H-bonds are shown by <i>blue dotted lines</i> . Other hydrogen atoms are omitted for clarity	131
Figure 6.26	H-bonding (N1H...N4) in a olanzapine 2-butoxyethanol solvate, b olanzapine dihydrate D, where water is present as cyclic tetramer, c cyclic tetramer, where water is present in type 2 and type 3 environments. H-bonds are shown by <i>blue colour</i> . Other hydrogen atoms are omitted for clarity.	131
Figure 6.27	Three 3-dimensional supramolecular constructs, a SC ₃₁ , b SC ₃₂ and c SC ₃₃ , formed by SC ₂₁ sheets (coloured by <i>cyan</i> and <i>blue</i> colour) in olanzapine solvates	132
Figure 6.28	Representative crystal structures of olanzapine solvates based on a SC ₃₁ -olanzapine-1,4-dioxane solvate hydrate; b SC ₃₂ -Olanzapine-acetic acid solvate and c SC ₃₃ -Olanzapine-TBMe hydrate; showing the position of solvent molecules within the crystal lattice	133

Figure 6.29	Plot of Random Forest classification error for molecular packing types of olanzapine solvates. The <i>black line</i> represents the error associated with the overall model. <i>Red, blue and green lines</i> represent the error associated with the molecular packing type classes; SC ₃₁ , SC ₃₂ and SC ₃₃	133
Figure 6.30	The MDS plot obtained from the Random Forest classification proximity matrix. Each of the 24 points represents a olanzapine solvate and is coloured according to crystal packing type: class 1 (<i>red</i>), class 2 (<i>green</i>) and class 3 (<i>blue</i>).	134
Figure 6.31	Variable dependency plots (SMR, apol, VdW_vol and b_count) for molecular packing types, SC ₃₁ , SC ₃₂ and SC ₃₃ . Numerical values for solvent descriptors are summarised in Table 6.9	137
Figure 6.32	Summary of crystal structure search for olanzapine. Each point represents a crystal structure classified by the conformational region, A or B, as defined in Fig. 6.4, and whether it contains the centrosymmetric dimer SC ₀ . The <i>open red diamond</i> and <i>square symbols</i> denote lattice energy minima corresponding to experimental structures, forms I and II respectively. The crystal energy landscape is comprised of the structures below -125 kJ mol^{-1} . A11 and A45 are the computed structures corresponding to form I and II respectively	138
Figure 6.33	Overlay of a experimental form I (<i>colour by element</i>) with A11 (<i>green</i>) and b experimental form II (<i>colour by element</i>) with A45 (<i>green</i>). The RMSD ₁₅ of these overlays are a 0.170 Å and b 0.225 Å	139
Figure 6.34	Comparison of a form I (calculated structure A11) and b calculated structure A1392, showing the arrangements of the common 2-D SCs; SC ₂₃ (based on stacking of SC ₁₂). The constructs are viewed along the axis of the t ₆ vector with the t ₈ axis (<i>red arrows</i>) running <i>left-right</i> across the page for the central layers, which are shown in <i>black</i> . In form I the upper and lower layers (<i>grey</i>) stack in parallel to the middle layer (<i>black</i>) while in A1392 they are rotated such that the top and bottom layers pack with opposite direction to that of the central layer. SC ₂₃ is not defined in Fig. 6.18, as it only occurs in one of the experimental structures, i.e. form I.	139
Figure 6.35	Comparison of a form II and b A162, showing the arrangement of the common 2-D SC, SC ₂₄ . The central constructs (<i>black</i>) are viewed along the axis of the t ₁₁ vector (shown by the <i>green circles</i>) with the t ₁₀ axis	

	running <i>left-right</i> across the page as indicated by the <i>red arrows</i> . The upper and lower layers in form II (<i>grey</i>) run parallel with t_{11} axis of the central construct while in A162 alternate layers pack in opposite directions ($-t_{11}$ indicated by the <i>blue circles</i>). SC_{24} , not shown in Fig. 6.18 as this 2-D construct was only observed in form II of the experimental structures included in the XPac analysis.	140
Figure 6.36	Multi-phase Pawley fit of unit cell of A162 against XRPD data of mixture of form III (major) and II (minor), observed profile (<i>blue</i>), calculated profile (<i>red</i>) and difference plot (<i>black</i>) in the range of 6–39° 2 θ . $R_{wp} = 6.152$	141
Figure 6.37	Top three pairwise intermolecular interactions in form I and form II, quantified in Table 6.11. The central molecule (colour by atom type and labelled as ‘C’) interacts with neighbouring molecule to form a (a) centrosymmetric dimer, SC_0 , b molecular pair involving hydrogen-bond (N1-H ... N2), and c molecular pair involving weaker molecule-molecule interaction	143
Figure 6.38	Packing coefficient (%) for the non-solvated polymorphs (<i>black</i>), co-crystals (<i>orange</i>) and solvates of OZPN. Solvate structures are coloured according to structural relationships. Specifically, SC_{31} , SC_{32} and SC_{33} are shown by <i>red</i> , <i>blue</i> and <i>green bars</i>	146
Figure 7.1	The four compounds studied in this thesis. Differences in the chemical structures within a group are highlighted in <i>red</i>	154
Figure 7.2	Principal component analysis score plot of solvent physicochemical properties, shown with an <i>ellipse</i> that represents the Hotelling T2 with 95 % confidence. 1-methylnaphthalene, dodecane, trichloroethylene and carbon tetrachloride were outliers from the 95 % confidence limit. Each <i>number</i> in the plot represents one solvent as mentioned below the <i>score plot</i>	156
Figure 7.3	Conformation ‘A’ of a clozapine, b amoxapine and c loxapine used for preliminary crystal structure prediction study and is also present in the experimental crystal structures (CSD refcodes: NDNHCL01, AMOXAP and NDOCLH01 for clozapine, amoxapine and loxapine respectively)	158
Figure 7.4	Scatter plot of solvents with positions according to the value of $t[1]$ and $t[2]$ from Fig. 7.2 and coloured according to crystallisation outcome: clozapine anhydrous form (<i>blue</i>), clozapine monohydrate (<i>magenta</i>), mixture of	

	clozapine anhydrous form and clozapine monohydrate (green), amorphous (orange), no sample obtained (cyan) and solvated form (maroon). Solvents not used in crystallisation condition are coloured grey. Plots shown for crystallisation conditions listed in Table 7.1: a solvent evaporation in vials at RT and b solvent evaporation on watch glass at RT	160
Figure 7.5	Scatter plot of solvents with positions according to the value of t[1] and t[2] from Fig. 7.2 and coloured according to crystallisation outcome: clozapine anhydrous form (blue), clozapine monohydrate (magenta), mixture of clozapine anhydrous form and clozapine monohydrate (green), amorphous phase (orange), no sample obtained (cyan) and solvated form (maroon). Solvents not used during crystallisation condition are coloured grey. Plots shown for crystallisation conditions listed in Table 7.1: a cooling crystallisation and b liquid-assisted grinding	161
Figure 7.6	Stack plot of XRPD patterns of physical forms of clozapine observed during experimental screening in the range of 5–35° 2 θ	163
Figure 7.7	STA thermograms of a clozapine anhydrous form, b clozapine N,N-dimethylacetamide and c clozapine monohydrate. DSC and TG curves are shown by black and blue colour, respectively	163
Figure 7.8	Overlay of the molecular conformations of olanzapine and clozapine which are present in the experimental crystal structures (RMSD of non-hydrogen atoms = 0.21 Å)	164
Figure 7.9	a , b Two views of the dimer formed by clozapine molecules, c 3-D arrangement of columns of clozapine dimers. Active H-bonds between dimers are shown by dotted black lines. Other hydrogen atoms are omitted for clarity.	165
Figure 7.10	a 2-D sheet structure formed by the two antiparallel chains of clozapine molecules (shown by red and blue colour) and N,N-dimethylacetamide molecules. H-bonds are shown by black dotted lines. b 3-D arrangement of sheets. All the hydrogen atoms are omitted for clarity.	166
Figure 7.11	3-D arrangement formed by the columns of the centrosymmetric dimers of clozapine in a clozapine monohydrate and b clozapine ethylene glycol solvate. H-bonds between clozapine and solvent molecules are shown by the blue dotted line. Other hydrogen atoms are omitted for clarity	167

Figure 7.12	Packing coefficient (%) for the anhydrous form (<i>red</i>), solvates (<i>orange</i>), analogues (<i>green</i>) of clozapine and anhydrous polymorphs (<i>blue</i>) of olanzapine	167
Figure 7.13	Chemical structures of clozapine and its analogues.	168
Figure 7.14	Summary of the preliminary crystal structure search of clozapine. Each <i>point</i> represents a hypothetical crystal structure/lattice energy minimum. The <i>cyan rectangle</i> with <i>open red diamond</i> represents the global minimum in the lattice energy, which corresponds to the known experimental structure.	169
Figure 7.15	The top three molecular pairs present in the crystal lattice of clozapine identified in Table 7.6. a Dimer involving hydrogen-bond between clozapine molecules (shown by <i>orange line</i>), b side-ways dimer, and c dimer involving weaker molecule-molecule interactions. The central molecule is labelled as 'C'	171
Figure 7.16	Top three pair-wise intermolecular interactions in a clozapine N,N-dimethylacetamide solvate and b, c clozapine monohydrate, quantified and labelled as in Table 7.7. The central molecule is labelled as 'C'. Other hydrogen atoms are omitted for clarity.	172
Figure 7.17	Stack plot of XRPD patterns of amoxapine raw material, melt quenched amorphous phase and partially recrystallised sample of amorphous amoxapine in the range of 10–35° 2 θ	174
Figure 7.18	DSC <i>curves</i> of amoxapine a heat-cool-heat cycle of amoxapine. The heat-cool-heat segments are shown by <i>blue, golden</i> and <i>black colour</i> respectively. In heating <i>curve, star</i> denotes an instrument artefact. b Amorphous amoxapine	174
Figure 7.19	a Layer structure formed by stacking of two types of chains (<i>highlighted in pink and green colour</i>) of amoxapine molecules. b The stacking of layers (shown by <i>red and blue colours</i>). All the hydrogen atoms are omitted for clarity	176
Figure 7.20	Summary of preliminary crystal structure search of amoxapine. Each <i>point</i> represents a hypothetical crystal structure/lattice energy minimum. The <i>blue square</i> with <i>open red diamond</i> represents the global minimum in lattice energy, which corresponds to the known experimental structure	177

Figure 7.21	Top five pairwise intermolecular interactions in amoxapine, quantified in Table 7.9, a , b molecular pairs involve contribution from C-H...Cl interaction (<i>black line</i>) and C-H...O interaction (<i>orange line</i>) and c a molecule-molecule interaction. The central molecule is labelled as 'C'	178
Figure 7.22	Overlay of the best simulated annealing solution with proton manually placed at succinic acid (co-crystal, <i>grey</i>) with the CASTEP geometry optimised structure (<i>black</i>) indicating proton transfer from succinic acid to loxapine. H-atom position before and the one obtained after geometry optimisation is denoted by H1 (SA) and H1 (DFT) respectively. Other hydrogen atoms are omitted for clarity. RMSD non-hydrogen atoms = 0.121Å	180
Figure 7.23	Final fit showing the observed y_{obs} (<i>lines</i>), calculated y_{calc} (<i>points</i>) and difference $[(y_{\text{obs}} - y_{\text{calc}})/\sigma(y_{\text{obs}})]$ profiles for the restrained Rietveld refinement of the best simulated annealing solution of loxapine hydrogen succinate	181
Figure 7.24	Scatter plot of solvents with positions according to the value of t[1] and t[2] from Fig. 7.2. Solvents are coloured according to the crystallisation outcome: form I (<i>blue</i>), form II (<i>magenta</i>), mixture of forms I and II (<i>green</i>), novel physical forms, solvates and/or salts (<i>red</i>), no sample obtained (<i>golden</i>) and no spectral information (<i>cyan</i>). Solvents which were not used in crystallisation are coloured <i>grey</i> . <i>Plots</i> are shown for crystallisation conditions listed in Table 7.3. a Solvent evaporation in vials and b solvent evaporation on watch glass	182
Figure 7.25	Scatter plot of solvents with positions according to the value of t[1] and t[2] from Fig. 7.2. Solvents are coloured according to the crystallisation outcome: form I (<i>blue</i>), form II (<i>magenta</i>), mixture of forms I and II (<i>green</i>), novel forms, solvates and/or salts (<i>red</i>) and no spectral information (<i>cyan</i>). Solvents which were not used in crystallisation are coloured <i>grey</i> . <i>Plot</i> is shown for cooling crystallisations, listed in Table 7.3	183
Figure 7.26	Stack plot of XRPD patterns of physical forms of loxapine identified during experimental screen	184
Figure 7.27	STA thermograms of loxapine form I (<i>red</i>) and form II (<i>blue</i>)	184
Figure 7.28	Overlay of the molecular conformations of amoxapine (<i>green</i>) and loxapine (<i>blue</i>) which are present in the experimental crystal structures (RMSD of non-hydrogen atoms = 0.08Å)	185

Figure 7.29	a 2-D packing of loxapine. b The staggered arrangement of sheets. Alternate sheets are shown by <i>red</i> and <i>blue</i> colour respectively. All the hydrogen atoms are omitted for clarity	185
Figure 7.30	a, b 1-D chains of loxapine molecules along <i>b</i> -axis. c The stacking of chains of loxapine molecules along <i>c</i> -direction. All the hydrogen atoms are omitted for clarity.	186
Figure 7.31	Summary of preliminary crystal structure search of loxapine. Each <i>point</i> represents a hypothetical crystal structure. The <i>violet triangle</i> with <i>open red square</i> represents one of the lowest energy structures, which corresponds to the known experimental structure	187
Figure 7.32	Top three molecular pairs in form I of loxapine, quantified in Table 7.12, a centrosymmetric dimer, b molecule-molecule interaction and c molecular pair involves C-H...O interaction (shown in <i>orange line</i>). The central molecule is labelled as 'C'. Other hydrogen atoms are omitted for clarity	189
Figure 7.33	Top three pairwise intermolecular interactions in form II of loxapine quantified in Table 7.12. a Molecular pair involving C-H...O (shown by <i>orange line</i>) and CH ₂ ... π interactions and b, c molecular pairs involving contribution from CH... π interactions. The central molecule is labelled as 'C'. Other hydrogen atoms are omitted for clarity	189
Figure 8.1	The four compounds studied in this thesis. The differences in the chemical structures within a group are highlighted in <i>red</i>	196
Figure 8.2	Schematic workflow developed in this work	197

List of Tables

Table 1.1	Different types of Intermolecular interactions involved in PIXEL calculations, their origin and their dependence on the intermolecular distance, r	17
Table 3.1	Compounds studied in this work	32
Table 4.1	Examples of high-throughput crystallisation carried out for physical form screening of pharmaceuticals	40
Table 4.2	Counter ions used for salt screening of amoxapine.	46
Table 4.3	Solvents used for physical form screening of clozapine in experiment 1 (PS-1) using 48-well plate	47
Table 4.4	Solvents used for physical form screening of clozapine in experiment 2 (PS-2) using 48-well plate	48
Table 4.5	Solvents used for physical form screening of olanzapine using 96-well plate	48
Table 4.6	Raman bands within the region of $1400\text{--}1700\text{ cm}^{-1}$ of Raman shift	51
Table 4.7	Details of 11 groups observed on the 96-well plate and their respective colour shown in Fig. 4.6	53
Table 4.8	Total number amoxapine salts identified from each counter acid during HTCAA	54
Table 4.9	Amoxapine salts classified by Raman spectra using group analysis on the results obtained in the screening experiment on the 96 well plate.	55
Table 4.10	Lattice parameters of the amoxapine salts identified from the salt screen	57
Table 4.11	Content of asymmetric unit of six novel salts of amoxapine reported in Table 4.10	59
Table 4.12	Solvent systems used in physical form screening, PS-1 of clozapine using a 48-well plate	60
Table 4.13	Solvent systems used in physical form screening, PS-2 of clozapine using a 48-well plate	62

Table 4.14	Physical form screening results of olanzapine using 96-well plate after group analysis based on Raman spectra	66
Table 4.15	Potential advantages and disadvantages of HTCAA methodology	70
Table 5.1	Confusion matrix generated by random forests for classification of dataset of 382 molecules	90
Table 5.2	Ten most important descriptors selected by random forests for classification model.	92
Table 6.1	Nomenclature for non-solvated polymorphs of olanzapine and their characteristic data [this work and from reference (Reutzel-Edens et al. 2003)]	101
Table 6.2	Summary of manual crystallisation conditions used in the experimental search	103
Table 6.3	The angles considered in the CrystalPredictor grid generation.	108
Table 6.4	Summary of crystallisation techniques used and summary of solid forms produced in the experimental search for physical forms of olanzapine	113
Table 6.5	Lattice parameters for olanzapine crystal structures found in the experimental search (standard uncertainties in parentheses)	115
Table 6.6	Results of spray drying experiments for olanzapine	123
Table 6.7	Highest-dimensionality SCs observed in the 35 olanzapine structures and forms obtained after desolvation	124
Table 6.8	Confusion matrix generated from Random Forest classification for the three molecular packing types of olanzapine solvates	134
Table 6.9	Numerical values of solvent descriptors obtained from variable dependency plots generated during Random Forests classification of olanzapine solvates.	137
Table 6.10	Partitioned intermolecular interaction energies (kJ mol^{-1}) from the PIXEL calculations of form I and II structures at 298 K, 123 K and 0 K	141
Table 6.11	Intermolecular interaction energies (kJ mol^{-1}) for the top three ranked pair-wise interactions in experimental form I and II at 298 K, 123 K and in predicted form I and II at 0 K.	142
Table 6.12	Partitioned intermolecular interaction energies (kJ mol^{-1}) from the PIXEL calculations of hypothetical structures A1 and A30	143

Table 6.13	Intermolecular interaction energies (kJ mol^{-1}) for the top two ranked dimer interactions in computed structures, A1 and A30 at 0 K.	144
Table 7.1	Summary of the manual crystallisation techniques used in the experimental search for physical forms of clozapine	157
Table 7.2	Summary of the manual crystallisation techniques used in the experimental search for physical forms of amoxapine	157
Table 7.3	Summary of the manual crystallisation conditions used in the experimental search for physical forms of loxapine	157
Table 7.4	Lattice parameters for clozapine crystal structures obtained in the experimental search (standard uncertainties in parentheses)	162
Table 7.5	Partitioned intermolecular interaction energies (kJ mol^{-1}) from the PIXEL calculations on clozapine anhydrous form, monohydrate and DMA solvate	170
Table 7.6	Intermolecular interaction energies (kJ mol^{-1}) for the top three ranked molecular pairs in the anhydrous form of clozapine	170
Table 7.7	Intermolecular interaction energies (kJ mol^{-1}) for top three ranked dimer interactions in clozapine monohydrate and N,N-dimethylacetamide solvate.	172
Table 7.8	Partitioned intermolecular interaction energies (kJ mol^{-1}) from the PIXEL crystal lattice calculations of amoxapine	177
Table 7.9	Intermolecular interaction energies (kJ mol^{-1}) for the top three ranked molecular pairs in amoxapine	177
Table 7.10	Lattice parameters for loxapine polymorph crystal structures (redeterminations) found in the experimental search (standard uncertainties in parentheses)	184
Table 7.11	Partitioned intermolecular interaction energies (kJ mol^{-1}) from the PIXEL calculations of loxapine polymorphs.	188
Table 7.12	Intermolecular interaction energies (kJ mol^{-1}) for the top three ranked dimer interactions in loxapine polymorphs.	188
Table 8.1	Recrystallisation methods used in this study to generate various solid forms	196
Table 8.2	List of the computational tools used in this study.	197
Table A.1	Solvent evaporation of olanzapine at room temperature (RT) and 277 K.	207

Table A.2	Fast solvent evaporation (on watch glass) of olanzapine at room temperature	209
Table A.3	Cooling/evaporative crystallisation of olanzapine on Automated Platform Crystalliser	210
Table A.4	Antisolvent crystallisation of olanzapine	214
Table A.5	Solution crystallisation of olanzapine on functionalised surfaces	215
Table A.6	Crystallisation of olanzapine by pH swing	216
Table A.7	X-ray crystallographic crystal data, data collection and refinement details for olanzapine and its solvates	217
Table A.8	Grinding experiments of olanzapine	226
Table A.9	Desolvation results of various olanzapine solvates	226
Table A.10	Recrystallisation of amorphous olanzapine under various conditions	227
Table A.11	Solvent evaporation of clozapine at room temperature	228
Table A.12	Fast solvent evaporation (on watch glass) of clozapine at room temperature	229
Table A.13	Cooling crystallisation of clozapine on React Array	230
Table A.14	Grinding results of clozapine	231
Table A.15	X-ray crystallographic crystal data, data collection and refinement details for clozapine and its solvates	232
Table A.16	Solvent evaporation of loxapine at room temperature	234
Table A.17	Cooling crystallisation of loxapine on React array	235
Table A.18	Fast solvent evaporation (on watch glass) of loxapine at room temperature	235
Table A.19	X-ray crystallographic crystal data, data collection and refinement details for amoxapine and loxapine crystal structures	236
Table A.20	X-ray crystallographic crystal data, data collection and refinement details for loxapine succinate and its monohydrate	237

Abbreviations

API	Active Pharmaceutical Ingredient
AXPN	Amoxapine
CBZ	Carbamazepine
CSD	Cambridge Structure Database
CSP	Crystal Structure Prediction
CT	Chlorothiazide
CZPN	Clozapine
DOE	Design of Experiment
E_C	Coulombic Energy
E_d	Dispersion Energy
E_p	Polarisation Energy
E_r	Repulsive Energy
E_{tot}	Total Lattice Energy
HCT	Hydrochlorothiazide
HTC	High Throughput Crystallisation
HTCAA	High Throughput Crystallisation and Analysis
LXPN	Loxapine
MWP	Multi-well Plate
OZPN	Olanzapine
PCA	Principal Component Analysis
QbD	Quality by Design
RF	Random Forests
RH	Relative Humidity
SC	Supramolecular Construct
SDPD	Structure Determination from Powder data
SXD	Single Crystal X-ray Diffraction
VT-XRPD	Variable Temperature X-ray Powder Diffraction
XRPD	X-ray Powder Diffraction